Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomized controlled trials by Goldie, Christina et al.
ORIGINAL ARTICLE
Niacin therapy and the risk of new-onset diabetes:
a meta-analysis of randomised controlled trials
Christina Goldie,1 Allen J Taylor,2 Peter Nguyen,3 Cody McCoy,4 Xue-Qiao Zhao,5
David Preiss1
▸ Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
heartjnl-2015-308055).
1BHF Glasgow Cardiovascular
Research Centre, University of
Glasgow, Glasgow, UK
2Medstar Research Institute,
Washington Hospital Center,
Washington DC, USA
3Division of Cardiology,
Medstar Georgetown University
Hospital, Washington DC, USA
4University of Tennessee Health
and Science Center, College of
Medicine, Memphis,
Tennessee, USA
5Cardiovascular Atherosclerosis
Research Laboratory, Division
of Cardiology, University of
Washington, Seattle,
Washington, USA
Correspondence to
Dr David Preiss, BHF Glasgow
Cardiovascular Research
Centre, University of Glasgow,
126 University Place,
Glasgow G12 8TA, UK;
david.preiss@glasgow.ac.uk
Received 27 April 2015
Revised 17 July 2015
Accepted 26 August 2015
▸ http://dx.doi.org/10.1136/
heartjnl-2015-308558
To cite: Goldie C, Taylor AJ,
Nguyen P, et al. Heart
Published Online First:
[please include Day Month
Year] doi:10.1136/heartjnl-
2015-308055
ABSTRACT
Objective Previous studies have suggested that niacin
treatment raises glucose levels in patients with diabetes
and may increase the risk of developing diabetes. We
undertook a meta-analysis of published and unpublished
data from randomised trials to conﬁrm whether an
association exists between niacin and new-onset
diabetes.
Methods We searched Medline, EMBASE and the
Cochrane Central Register of Controlled Trials, from
1975 to 2014, for randomised controlled trials of niacin
primarily designed to assess its effects on cardiovascular
endpoints and cardiovascular surrogate markers. We
included trials with ≥50 non-diabetic participants and
average follow-up of ≥24 weeks. Published data were
tabulated and unpublished data sought from
investigators. We calculated risk ratios (RR) for new-
onset diabetes with random-effects meta-analysis.
Heterogeneity between trials was assessed using the
I2 statistic.
Results In 11 trials with 26 340 non-diabetic
participants, 1371 (725/13 121 assigned niacin; 646/
13 219 assigned control) were diagnosed with diabetes
during a weighted mean follow-up of 3.6 years. Niacin
therapy was associated with a RR of 1.34 (95% CIs
1.21 to 1.49) for new-onset diabetes, with limited
heterogeneity between trials (I2=0.0%, p=0.87). This
equates to one additional case of diabetes per 43 (95%
CI 30 to 70) initially non-diabetic individuals who are
treated with niacin for 5 years. Results were consistent
regardless of whether participants received background
statin therapy (p for interaction=0.88) or combined
therapy with laropiprant (p for interaction=0.52).
Conclusions Niacin therapy is associated with a
moderately increased risk of developing diabetes
regardless of background statin or combination
laropiprant therapy.
INTRODUCTION
Despite apparently beneﬁcial effects on total-
cholesterol and high-density lipoprotein (HDL)
cholesterol, recently published data from major
trials of the lipid-modifying agent niacin have
shown no cardiovascular beneﬁt when niacin is
added to background statin therapy.1 2 These results
from the Atherothrombosis Intervention in
Metabolic Syndrome with Low HDL/High
Triglycerides: Impact on Global Health Outcomes
(AIM-HIGH) trial and the Heart Protection Study
2-Treatment of HDL to Reduce the Incidence of
Vascular Events (HPS2-THRIVE) trial contrast with
ﬁndings from the Coronary Drug Project, conducted
in the prestatin era, which showed a 17% reduction
in non-fatal myocardial infarction (MI) or death
from coronary causes.3 Major niacin clinical trials
have provided insights into its effect on cardiovascu-
lar outcomes and its non-cardiovascular effects.
While it has long been known that niacin therapy
can cause cutaneous ﬂushing, leading to various
approaches to counteract this side effect, other det-
rimental effects have been noted.2 4
One potentially important side effect known to
occur on niacin is a rise in glucose levels in those
with diabetes.5 Findings from a post-hoc analysis of
the Coronary Drug Project suggested that this
effect also occurred in those without diabetes,
leading to an increase in the risk of developing dia-
betes.6 However, data regarding new-onset diabetes
in trials of niacin therapy have not previously been
systematically collected and pooled, and the recent
publication of two major trials of niacin therapy
presents an opportunity to do so.1 2 It is also
unclear whether any effect on new-onset diabetes is
inﬂuenced by background statin therapy or whether
treatment using the combination of niacin and laro-
piprant may have different effects compared with
niacin therapy without laropiprant. Conclusive evi-
dence that niacin adversely inﬂuences diabetes risk
would be an important consideration when asses-
sing risks and beneﬁts of this treatment. We there-
fore conducted a meta-analysis of published and
unpublished data to investigate niacin’s effect on
new-onset diabetes.
METHODS
Search strategy and selection criteria
We gathered data from randomised controlled trials
of niacin primarily designed to assess its impact on
cardiovascular outcomes including both cardiovas-
cular events and cardiovascular surrogate markers.
We excluded trials that randomised fewer than 50
non-diabetic participants, those with a follow-up
period of less than 24 weeks, and those conducted
solely in patients with diabetes. Only trials compar-
ing niacin to a relevant comparator were included:
placebo, no therapy, standard care or a prespeciﬁed
list of lipid-modifying agents, namely bile acid
sequestrants or ezetimibe based on the rationale
that these are considered unlikely to alter diabetes
risk. We excluded any trials that directly compared
niacin to statin therapy or ﬁbrate therapy based on
the rationale that these comparator agents may
inﬂuence diabetes risk. Combination therapy trials
were allowed as long as the other lipid-modifying
therapy or therapies involved were balanced
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between the niacin arm and the control arm. Trials in which
niacin was combined with laropiprant were included. Data for
trials only comparing different doses of niacin without any
placebo-treated or untreated arms were not considered relevant.
Some trials included three or more arms and in such cases we
only included those arms that met the criteria described above,
and pooled them as required for analysis.
We searched Medline, EMBASE and the Cochrane Central
Register of Controlled Trials for randomised controlled trials
with the medical subject heading (MeSH) terms ‘niacin’, ‘nicoti-
nic acid’ or ‘Niaspan’ as title words and keywords (see ﬁgure 1).
We restricted our search to between the years 1975 and 2014,
trials that involved adult patients, and reports that were pub-
lished in English. We undertook our search on 18 June 2014,
and identiﬁed 1163 reports. An additional two reports were
added on 17 July 2014 as incident diabetes data became avail-
able for two major studies, namely AIM-HIGH and
HPS2-THRIVE.1 2 Reports were independently reviewed by
two readers (CG and DP), and any discrepancies were resolved
by consensus.
Data sources
For the eight trials that had published data on new-onset dia-
betes,2 4 6–11 information on the number of non-diabetic partici-
pants at baseline and cases of incident diabetes were
independently abstracted by two authors (CG and DP) and tabu-
lated. One trial that had found no cases of new-onset diabetes
was excluded.12 We contacted investigators from eight other
trials meeting our search criteria in which incident diabetes data
remained unpublished and, using a formal questionnaire sheet
(see online supplementary eFigure 1), we received and included
data from three of these trials.13–15 Eleven trials were therefore
included in the ﬁnal analysis, of which eight had previously pub-
lished data for incident diabetes and three had not. For the
Figure 1 Flow diagram of literature search to identify randomised controlled niacin trials.
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Table 1 Data for non-diabetic participants in 11 trials included in meta-analysis
Trial Active vs control daily therapies
Non-DM patients/
total cohort (%)
N (without DM)
on niacin/
control Description
Follow-up
(months)
Method of DM
diagnosis
Mean BMI
(kg/m2)
Mean age
(years)
Frequency of
within-trial FPG
measurement
Coronary drug
project6
Niacin 3 g vs placebo 3436/3906 (88) 988/2448 Men with previous MI 60 I, II, III 26.1 52.5 Yearly
FATS7 Niacin 4 g/colestipol 30 mg vs placebo
or placebo/colestipol 30 mg
82/82 (100) 36/46 Men with high ApoB and family
history of CHD
32 II 26.7 46.7 6 monthly
ADMIT8 Niacin 3 g vs placebo 343/468 (73) 173/170 Peripheral artery disease, with
and without DM
11 II 27 65 6 weekly
ARBITER-213 ERN 1 g vs placebo (background
statin)
121/167 (72) 63/58 CHD and HDL <1.16 mmol/L 12 II, III 29.1* 67* At 12 months
Moore et al15 ERN 2 g/atorvastatin±colsevelam 3.8 g
vs placebo/atorvastatin
108/123 (88) 70/38 CHD or carotid atherosclerosis
with high ApoB and LDL-c
12 I, II, III 29.6* 55* At months 5 and 12
SEACOAST I9 ERN 1 g/simvastatin 20 mg or 2 g/
20 mg vs simvastatin 20 mg
248/314 (79) 150/98 High CVD risk with mixed
dyslipidaemia
4 Not stated 28.2* 56.6* At week 24
Guyton et al10 ERN 2 g/ezetimibe 10 mg/simvastatin
20 mg vs ezetimibe 10 mg/
simvastatin 20 mg
798/942 (85) 569/229 Type IIa or Type IIIb
hyperlipidaemia
16 I, II, III 30.1* 57.2* 4 weekly
Maccubbin
et al11
ERN 2 g/LRPT 40 mg or ERN 2 g vs
placebo (with or without background
statin)
1356/1613 (84) 1124/232 Primary hypercholesterolaemia
or mixed dyslipidaemia
4 I, II 29* – At week 24
ARBITER-614 ERN 2 g vs ezetimibe 10 mg
(background statin)
218/363 (60) 114 /104 CHD or high CHD-risk, with LDL
<2.6 mmol/L and low HDL
14 II, III 30.9* 64.5* At months 2, 8 and 14
AIM-HIGH1 ERN 1.5–2 g/simvastatin 40–80 mg vs
placebo/simvastatin 40–80 mg (with
or without ezetimibe 10 mg)
2256/3414 (66) 1130/1126 Atherosclerotic CVD and LDL
<1.81 mmol/L
36 Not stated – 63.7* 6 monthly
HPS2-THRIVE2 ERN 2 g/LRPT 40 mg/simvastatin
40 mg vs placebo/simvastatin 40 mg
(with or without ezetimibe 10 mg)
17 374/25 673 (68) 8704/8670 Patients with CVD 47† I, II 27.7* 64.9* None
Total 26 340/37 065 (71) 13 121/13 219
I=adverse event report or physician report; II=glucose lowering therapy; III=raised fasting plasma glucose (≥7.0 mmol/L) on two occasions.
*Data from total cohort (including diabetics at baseline).
‡Weighted mean follow-up.
AIM-HIGH, Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes; BMI, body mass index; CHD, coronary heart disease; CVD, cardiovascular disease; DM, diabetes mellitus; ERN,
extended release niacin; FPG, fasting plasma glucose; HPS2-THRIVE, Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events; HDL,high-density lipoprotein; LDL, low-density lipoprotein; LRPT, laropiprant;
MI, myocardial infarction.
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three trials with unpublished data, incident diabetes data had
not been analysed prior to our request. The study was con-
ducted in accordance with PRISMA guidance.16
Endpoints
A patient was considered to have developed diabetes during a
trial if: there was an adverse event report of new-onset diabetes
mellitus; the participant commenced oral diabetes medication or
insulin; the participant had two post-baseline fasting plasma
glucose values ≥7.0 mmol/L.
Quality assessment
Two authors (CG and DP) independently evaluated the quality
of each of the trials, using a well-established tool.17 Nine
characteristics were assessed: randomisation, concealment of
treatment allocation, baseline similarity of randomised groups,
eligibility criteria, outcome assessor blinding, care provider
blinding, patient blinding, availability of point estimates and
measures of variability and intention to treat analysis.
Assessment of these criteria allowed each trial to be awarded a
Delphi score of 0–9 with a higher score indicating higher
quality.
Statistical analysis
To identify the potential effect of niacin on incident diabetes,
we calculated an overall risk ratio (RR), with associated 95%
CIs, as the ratio of cumulative incidence from the available data
for all non-diabetic participants at baseline and for those who
developed diabetes during trial follow-up. Study-speciﬁc RRs
were pooled in a random-effect model meta-analysis. We
assessed statistical heterogeneity across all studies using the I2
statistic, which is derived from Cochrane’s Q ((Q−df/Q)×100)
and provides a measure of the proportion of overall variation
attributable to the heterogeneity between studies.
Despite using both published and unpublished data, we none-
theless formally investigated publication bias by producing a
funnel plot and undertaking an Egger test. We additionally
undertook sensitivity analyses, using the ﬁxed-effect inverse-
variance method, to compare trials that had and had not used
laropiprant in combination with niacin, and to compare trials
that had and had not used background statin treatment. We
repeated the main analysis after excluding the largest trial and
also performed an analysis using a ﬁxed-effects model. All
p values were two-sided, and p<0.05 was considered statistically
signiﬁcant. We analysed data with StataSE V.13 (StataCorp).
RESULTS
The 11 trials included in the meta-analysis provided data on
26 340 participants without diabetes at baseline (baseline
characteristics in table 1). Over a weighted mean follow-up dur-
ation of 3.6 years, 1375 (5.22%) were diagnosed with diabetes.
Of those treated with niacin, 725 (5.53%) out of 13 121 partici-
pants developed diabetes while, on control treatment, 646
(4.89%) out of 13 219 developed diabetes. This represents a
RR of 1.34 (95% CI 1.21 to 1.49) (see ﬁgure 2). Expressed in
absolute terms, treating 43 (95% CI 30 to 70) initially non-
Figure 2 Association between niacin therapy and incident diabetes in 11 trials. (Ordered by weight contributed to meta-analysis.) AIM-HIGH,
Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes; HPS2-THRIVE, Heart
Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events.
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diabetic individuals with niacin for 5 years would result in one
additional case of diabetes being diagnosed compared with no
treatment.
Heterogeneity across trial results was limited (0.0%, p=0.87).
There was no evidence of publication bias according to either
the Egger test (p=0.15) or funnel plot (see online supplemen-
tary eFigure 2). The trials were generally found to be of high
quality (median Delphi score 9, range 6–9).
Sensitivity analyses demonstrated no difference between the
trials that had combined laropiprant with niacin and the trials
that had not (p=0.52 for interaction; see online supplementary
eFigure 3). Similarly, no difference was observed when compar-
ing the trials that had or had not used background statin treat-
ment (p=0.84 for interaction; see online supplementary
eFigure 4). We performed an analysis with the largest trial,
HPS2-THRIVE (which provided 65% of the overall weighting
of the main analysis), excluded. In the remaining 10 trials, the
RR of new-onset diabetes on niacin was similarly elevated at
1.38 (95% CI 1.16 to 1.65). Finally, we repeated the
meta-analysis using ﬁxed-effects modelling, and the results were
very similar to the main analysis, namely RR 1.35 (95% CI 1.21
to 1.50).
DISCUSSION
This comprehensive meta-analysis of published and unpublished
data from randomised controlled trials of niacin demonstrates
that niacin therapy led to a 34% increase in the risk of develop-
ing diabetes compared with placebo or standard care. These
ﬁndings complement previous study reports that have shown
deteriorations in glycaemic control in patients with diabetes on
niacin. Results were also consistent regardless of the presence or
absence of background statin therapy or concomitant laropipr-
ant therapy.
The mechanism that explains niacin’s detrimental effect on
glycaemic control and diabetes risk remains unclear. The obser-
vation that statins also increase diabetes risk and that this
appears to be an on-target effect18 suggests that a speciﬁc lipid-
modifying effect warrants particular attention. The Mendelian
randomisation approach taken by Swerdlow et al to establish
whether the modest increase in diabetes risk on statins is an
on-target or off-target effect may be applicable for niacin. The
data from HPS2-THRIVE also conﬁrm that clinically signiﬁcant
deteriorations in glucose control in patients with diabetes are
substantially increased on niacin. In those known to have dia-
betes at baseline in this major trial, there was a 55% increase in
serious disturbances in glucose control for patients with dia-
betes, most of whom required hospital admission as a result.2
These ﬁndings contrast with earlier and smaller trials with
shorter follow-up which suggested that the detrimental effect of
niacin on glucose may only be temporary and therefore of
potentially limited clinical importance.8 10 Additionally, the
Coronary Drug Project showed that the relative risk of develop-
ing diabetes on niacin was similar regardless of whether patients
had impaired fasting glycaemia (IFG) or normoglycaemia
though the absolute risk was higher in IFG due to the increased
rate of progression to diabetes.6
Even with the discovery that statins modestly increase diabetes
risk, their cardiovascular beneﬁts still greatly outweigh any such
metabolic risk. With niacin, the risk:beneﬁt ratio appears far less
favourable. Recent major niacin trials have now conﬁrmed a
lack of cardiovascular beneﬁt when niacin is added to statin
therapy and increased risk of a variety of adverse events along
with the expected increase in cutaneous ﬂushing. In
HPS2-THRIVE, gastrointestinal events, musculoskeletal events
and infectious adverse events were increased on niacin.2 The
AIM-HIGH trial recently released supplementary data detailing
all adverse events seen during the trial. Here again, increases
were seen in gastrointestinal events and infectious events com-
pared with placebo.4 The results from HPS2-THRIVE and
AIM-HIGH differ from the historical Coronary Drug Project, a
clinical trial of niacin monotherapy which suggested modest car-
diovascular beneﬁt with similar effects across all glycaemic cat-
egories.3 19 As a result of these disappointing cardiovascular
trials, combination therapy of niacin with laropiprant has been
withdrawn from the market. However, extended release niacin
is still available for prescription in the USA in brand and generic
versions.
One of the strengths of this analysis is that we were able to
include data (published and unpublished) from almost all rele-
vant niacin trials, thereby maximising our ability to conﬁrm any
effect. Five trials were not included in this meta-analysis, due to
the unavailability of unpublished data12 20–24 but these were
relatively small studies whose inclusion would not have changed
the main ﬁndings. These trials would have provided information
on 634 non-diabetic trial participants, only 2.4% of the total
cohort. Additionally, there was a very low level of heterogeneity
across trial results. Although no large-scale trials of niacin are
likely to be undertaken in the future, it would appear sensible
to include new-onset diabetes as a prespeciﬁed endpoint in
major future trials of lipid-modifying agents.
An important weakness of our analysis is that no trials were
speciﬁcally designed to assess new-onset diabetes, and new-onset
diabetes was only a prespeciﬁed endpoint in one major trial. We
were unable to compare the effects of niacin on diabetes risk
Key messages
What is already known on this subject?
Previous studies have suggested that niacin therapy may have a
detrimental effect on glycaemic control in those with diabetes,
and may increase the risk of developing diabetes. Data from all
niacin trials have not previously been pooled to systematically
examine the risk of niacin’s risk on new-onset diabetes, and it is
also unknown whether any relationship may be affected by
concomitant statin (statins have been shown to have a
diabetogenic effect themselves) or laropiprant (DP1 antagonist)
therapy.
What might this study add?
We systematically collected and pooled data regarding
new-onset diabetes from 11 trials of niacin, involving 26 340
patients. Niacin therapy led to a 34% higher risk of developing
diabetes. This effect was not inﬂuenced by the presence or
absence of statin therapy or by coadministration with
laropiprant.
How might this impact on clinical practice?
Failure in two major clinical trials (AIM HIGH, HPS2-THRIVE)
when niacin was added to statin therapy led to the withdrawal
of the drug in Europe. However, the other brand and generic
versions are still in use in the USA and elsewhere, and
proponents of niacin argue that the cardiovascular beneﬁt of
niacin monotherapy observed in the Coronary Drug Project
suggests that niacin should still be used in some patients. Our
data suggest that new-onset diabetes is a major concern with
this agent.
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and cardiovascular events respectively to provide a fuller clinical
context, and we could also not compare risks across subgroups
of diabetes risk factors like fasting glucose and body mass index
(BMI). Analyses were conducted without access to individual
participant data. It is also unclear if niacin therapy alters micro-
vascular disease risk over time in those who develop diabetes. In
order to estimate the average follow-up, we assumed the median
approximated to the arithmetic mean for some trials and, in
several trials, the quoted mean BMI and mean age at baseline
are averages taken from the full cohort because speciﬁc data for
non-diabetic participants were unavailable.
In summary, this analysis conﬁrms that niacin increases the
risk of developing diabetes by about 35% and that this risk
occurs regardless of whether concomitant statin therapy or com-
bination therapy with laropiprant is used.
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